Earnings ·
Reports Q3 revenue of $226.8M and expects merger with Indivior to close November 2
SUPNSupernus, Inc.
Supernus Pharmaceuticals reported third-quarter total revenues of $226.8 million, an 18% increase from the prior year period, driven by strong growth in its four key products: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. Net product sales reached $178.6 million, while collaboration revenue from Biogen’s ZURZUVAE sales totaled $41.7 million. The company also raised its full-year 2026 total revenue guidance to a range of $875 million to $900 million and adjusted operating earnings guidance to $160 million–$180 million. Additionally, Supernus announced that its all-stock merger with Indivior Pharmaceuticals is expected to close on November 2, 2026, creating a diversified CNS biopharmaceutical leader. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.